Janux Therapeutics (JANX) Enterprise Value (2020 - 2025)
Historic Enterprise Value for Janux Therapeutics (JANX) over the last 6 years, with Q3 2025 value amounting to -$989.0 million.
- Janux Therapeutics' Enterprise Value fell 5029.58% to -$989.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$989.0 million, marking a year-over-year decrease of 5029.58%. This contributed to the annual value of -$1.0 billion for FY2024, which is 19799.12% down from last year.
- Latest data reveals that Janux Therapeutics reported Enterprise Value of -$989.0 million as of Q3 2025, which was down 5029.58% from -$996.0 million recorded in Q2 2025.
- Janux Therapeutics' Enterprise Value's 5-year high stood at -$303.3 million during Q2 2023, with a 5-year trough of -$1.0 billion in Q4 2024.
- Over the past 5 years, Janux Therapeutics' median Enterprise Value value was -$384.6 million (recorded in 2021), while the average stood at -$563.4 million.
- In the last 5 years, Janux Therapeutics' Enterprise Value crashed by 469924.48% in 2021 and then skyrocketed by 5134.41% in 2022.
- Over the past 5 years, Janux Therapeutics' Enterprise Value (Quarter) stood at -$375.0 million in 2021, then grew by 12.79% to -$327.0 million in 2022, then fell by 5.2% to -$344.0 million in 2023, then plummeted by 197.99% to -$1.0 billion in 2024, then increased by 3.53% to -$989.0 million in 2025.
- Its last three reported values are -$989.0 million in Q3 2025, -$996.0 million for Q2 2025, and -$1.0 billion during Q1 2025.